Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cadrenal TherapeuticsCVKD -2.96%30 Current Ratio is 2.68 as of Mar. 2026, which is 28% below its 10-year median of 3.71. GuruFocus rates CVKD with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Cadrenal Therapeutics ranks worse than 60.2% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cadrenal Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 2.68.
Cadrenal Therapeutics has a current ratio of 2.68. It generally indicates good short-term financial strength.
The historical rank and industry rank for Cadrenal Therapeutics's Current Ratio or its related term are showing as below:
CVKD'
s Current Ratio Range Over the Past 10 Years
Min: 0.55 Med: 3.71 Max: 16.45
Current: 2.68
During the past 4 years, Cadrenal Therapeutics's highest Current Ratio was 16.45. The lowest was 0.55. And the median was 3.71.
CVKD's Current Ratio is ranked worse than 60.2% of 1412
companies
in the Biotechnology industry
Industry Median: 3.86
vs CVKD: 2.68
Cadrenal Therapeutics (NAS:CVKD) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cadrenal Therapeutics Current Ratio Related Terms
Cadrenal Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Cadrenal Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVKD vs RVPH, IMNN, ACXP: Current Ratio Comparison
For the Biotechnology subindustry, Cadrenal Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cadrenal Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cadrenal Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cadrenal Therapeutics (CVKD) has a Current Ratio of 2.68 as of Mar. 2026. This is 28% below median its historical median of 3.71. Over the past decade, Cadrenal Therapeutics' Current Ratio has ranged from 0.55 to 16.45. According to the industry distribution chart, Cadrenal Therapeutics ranks #850 out of 1412 companies in the Biotechnology industry, placing it in the top 60.2%.
Is Cadrenal Therapeutics' Current Ratio too high?
Cadrenal Therapeutics' current Current Ratio of 2.68 is 28% below median its 10-year median of 3.71. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 16.45. The Biotechnology industry median Current Ratio is 3.86. Cadrenal Therapeutics' value of 2.68 is 30.6% below this industry median. Based on the distribution chart, Cadrenal Therapeutics ranks #850 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cadrenal Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cadrenal Therapeutics' Current Ratio compare to RVPH and IMNN?
According to the Biotechnology industry distribution chart, Cadrenal Therapeutics ranks #850 out of 1412 companies for Current Ratio. This places Cadrenal Therapeutics in the lower half of its industry. The industry median Current Ratio is 3.86. Cadrenal Therapeutics' value of 2.68 is 30.6% below this benchmark. Historically, Cadrenal Therapeutics' own Current Ratio has ranged from 0.55 to 16.45 over the past decade. While the company's 10-year median is 3.71 vs. the industry median of 3.86, Cadrenal Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.86, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cadrenal Therapeutics's current Current Ratio of 2.68 is 30.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cadrenal Therapeutics's current Current Ratio is 2.68, which is 28% below median its own 10-year median of 3.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cadrenal Therapeutics stock overvalued right now?
Cadrenal Therapeutics (CVKD) has a current Current Ratio of 2.68. The current Current Ratio is 2.68, which is 28% below median its 10-year median of 3.71 and 30.6% below the Biotechnology industry median of 3.86. Cadrenal Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cadrenal Therapeutics (CVKD), the current Current Ratio is 2.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
30GF Score
Get the complete analysis for CVKD
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVKD has been successfully added to your 
